Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis

OBJECTIVE: To evaluate the long-term safety and efficacy of adalimumab in patients with ankylosing spondylitis (AS) and total spinal ankylosis (TSA). DESIGN: Patients (n = 315) with active AS were randomised in a 2:1 ratio to receive adalimumab 40 mg every other week or placebo for 24 weeks followed...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, D, Pangan, A L, Schiff, M H, Braun, J, Borofsky, M, Torre, J, Davis, J C, Wong, R L, Kupper, H, Collantes, E
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2008
Materias:
Extended Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564805/
https://www.ncbi.nlm.nih.gov/pubmed/18056755
http://dx.doi.org/10.1136/ard.2007.082529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564805/
https://www.ncbi.nlm.nih.gov/pubmed/18056755
http://dx.doi.org/10.1136/ard.2007.082529

Ejemplares similares